Cytokinetics Incorporated
12/19/2025 | Press release | Distributed by Public on 12/19/2025 15:02
Material Event (Form 8-K)
Item 8.01 Other Events.
On December 19, 2025, Cytokinetics, Incorporated announced that the U.S. Food and Drug Administration ("FDA") has approved MYQORZO™ (aficamten), 5 mg, 10 mg, 15 mg, 20 mg tablets, for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy ("oHCM") to improve functional capacity and symptoms. MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract ("LVOT") obstruction.
Cytokinetics Incorporated published this content on December 19, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on December 19, 2025 at 21:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]